Sabadell Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sabadell Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.78M	Sell	14,642 -1,029	-7%	-$204K	0.58%	50
2023 Q1	$3.15M	Sell	15,671 -534	-3%	-$112K	0.67%	50
2022 Q4	$3.65M	Sell	16,205 -22,977	-59%	-$4.9M	0.76%	53
2022 Q3	$7.88M	Buy	39,182 +4,650	+13%	+$887K	1.73%	19
2022 Q2	$4.78M	Hold	34,532	–	–	1.01%	30
2022 Q1	$5.6M	Buy	+34,532	New	+$5.26M	0.97%	29

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sabadell Asset Management's ALNY Position: Q2 2023 in Review

Sabadell Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 6.6% in Q2 2023, selling an estimated $204K and leaving 14,642 shares worth $2.78M. The position accounts for 0.58% of the portfolio, ranked #50.

Sabadell Asset Management first reported a position in ALNY in Q1 2022 and has held it in 6 quarters since. The position peaked at $7.88M in Q3 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Sabadell Asset Management held 14,642 shares of Alnylam Pharmaceuticals worth $2.78M as of Q2 2023.
Sabadell Asset Management sold 1,029 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $204K.
Alnylam Pharmaceuticals made up 0.58% of Sabadell Asset Management's portfolio in Q2 2023, its #50 holding.
Sabadell Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
Sabadell Asset Management's Alnylam Pharmaceuticals position peaked at $7.88M in Q3 2022.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Sabadell Asset Management's 13F filing for Q2 2023, filed 23 Jan 2024.